Merus报告了中期2期数据，显示Petosemtamab + Pembrolizumab在正在进行的试验中的缓解率为63%，12个月总生存率为79%，该数据将在ASCO 2025上发布，电话会议定于5月22日举行

-  63% response rate observed among 43 evaluable patients

-  79% overall survival rate at 12-months; 9 months median progression-free survival

-  Conference Call on Thursday, May 22 at 5:30 p.m. ET

 

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Carla M. L. van Herpen M.D. Ph.D., Radboud University Medical Center, Nijmegen, Netherlands at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting on Monday, June 2 at 9 a.m. - 12:00 p.m. CT.